Reducing Treatment Burden in AMD | Zendy

Rajendra S. Apte | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Reducing Treatment Burden in AMD

Author(s) -

Rajendra S. Apte

Publication year - 2020

Publication title -

cell

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 26.304

H-Index - 776

eISSN - 1097-4172

pISSN - 0092-8674

DOI - 10.1016/j.cell.2020.02.028

Subject(s) - aflibercept , biology , macular degeneration , retinal , bench to bedside , disease , vegf receptors , antagonist , pharmacology , intensive care medicine , ophthalmology , medicine , bevacizumab , cancer research , receptor , genetics , medical physics , chemotherapy , biochemistry

VEGF-A antagonists have revolutionized wet AMD treatment. Several challenges remain including high treatment burden requiring repeated intraocular injections for persistent disease. Brolucizumab directly inhibits VEGF-A function, providing visual outcomes comparable to aflibercept (an FDA-approved VEGF-A antagonist). Anatomic retinal outcomes including retinal fluid, a marker of disease activity, favored brolucizumab. To view this Bench to Bedisde, open or download the PDF.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research